Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.
Type:
Application
Filed:
June 22, 2017
Publication date:
October 31, 2019
Applicants:
Universite Paris EST Creteil Val de Marne, Institut National de la Recherche Medicale (Inserm), Assistance Publique Hopitaux de Paris, Universite Paris 6 Pierre et Marie Curie, Centre National de la Recherche Scientifique
Inventors:
Sébastien MAURY, José COHEN, Benoît SALOMON, Sina NASERIAN, Mathieu LECLERC
Abstract: A method is provided for producing a recombinant pseudotyped viral vector particle wherein a cell is transfecting with (i) at least one vector construct; (ii) at least one packaging construct; and (iii) an expression construct encoding a chimeric glycoprotein encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1 to yield a producer cell, followed by culturing the producer cell in a medium; and separating the producer cell from the medium to recover the recombinant viral vector particle from the medium. Vectors obtained in this manner have significantly higher titers than vectors coated with the parental non-chimeric glycoprotein.
Type:
Grant
Filed:
November 14, 2012
Date of Patent:
July 28, 2015
Assignees:
INSTITUT NATIONAL DE LA RECHERCHE MEDICALE (INSERM), INSTITUT CLAYTON DE LA RECHERCHE
Abstract: The invention relates to monovalent ligands of the human CD28 receptor, which can selectively block the interaction between CD28 and B7 without activating the CD28 receptor. Said ligands can be used in particular in the production of immunosuppressant drugs, selectively blocking T lymphocyte activation phenomena involving the CD28 receptor.
Type:
Application
Filed:
October 8, 2010
Publication date:
March 7, 2013
Applicants:
Institut National de la Recherche Medicale(Inserm), Effimune